Attovia Stock

attovia.comHealthcare / BioTech & PharmaFounded: 2023Funding to Date: $165.85MM

Attovia is a biotechnology company which offers therapeutic solutions to pharmaceutical companies and healthcare providers. Their platform utilizes a biparatopic nanobody approach in developing potential therapies for complex diseases. By focusing on previously untreatable conditions, Attovia strives to advance drug discovery and provide innovative solutions for unmet medical needs. This company was founded by Tao Fu, Yuling Luo Ph.D, Hangjun Zhan Ph.D, David Bellovin Ph.D, and Petter Veiby Ph.D in 2023 and is headquartered in Fremont, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Attovia, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

Attovia Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Attovia Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
05/09/2024 Series B $105MM $xx.xx $273.65MM Goldman Sachs Asset Management, Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, Logos Capital, Frazier Life Sciences, Illumina Ventures, venBio Partners
Price per Share
$xx.xx
Shares Outstanding
76,363,636
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Goldman Sachs Asset Management, Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, Logos Capital, Frazier Life Sciences, Illumina Ventures, venBio Partners
06/20/2023 Series A-2 $30.42MM $xx.xx $159.73MM Frazier Life Sciences, Illumina Ventures, venBio Partners
Price per Share
$xx.xx
Shares Outstanding
27,659,090
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Frazier Life Sciences, Illumina Ventures, venBio Partners
06/20/2023 Series A-1 $30.43MM $xx.xx $159.73MM Frazier Life Sciences, Illumina Ventures, venBio Partners
Price per Share
$xx.xx
Shares Outstanding
30,425,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Frazier Life Sciences, Illumina Ventures, venBio Partners

Attovia investors also invested in these private companies

Leadership & Board

Leadership

Yuling Luo Ph.D
Co-Founder
Tao Fu
Co-Founder
Hangjun Zhan Ph.D
Chief Technology Officer

Attovia stock FAQs

plusminus

Can you buy Attovia stock?

As Attovia is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Attovia, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Attovia stock?

To invest in a private company like Attovia through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Attovia stock?

Yes, you may sell the Attovia stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Attovia stock?

If you hold private company shares of Attovia – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Attovia on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Attovia a public company?

No, Attovia is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Attovia’s stock price?

Attovia is a privately held company and therefore does not have a public stock price. However, you may access Attovia private market stock price with Forge Data.
plusminus

What is Attovia’s stock ticker symbol?

Attovia does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Attovia’s news and media highlights

Bay Area–based Attovia Therapeutics announced Thursday it has secured a $105 million Series B as it looks to advance assets in the hot immunology and inflammation space. According to biotech entrepreneur Andrew Pannu, the immunology and inflammation (I&I) sector saw $12.3 billion in therapeutic M&A activity last year and would continue to be attractive to investors. In addition, I&I biotech Apogee Therapeutics closed an upsized public offering in March, netting around $483 million.
Attovia Therapeutics, a biotech company pioneering spatially optimized biparatopic biologics, announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody. Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline.
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.